New drug trial targets scarring kidney disease
NCT ID NCT07268638
Summary
This study is testing whether an investigational drug called praliciguat can help control focal segmental glomerulosclerosis (FSGS), a disease that causes scarring in the kidneys' filters. The trial will involve 60 adults with confirmed FSGS who will take either the drug or a placebo for 24 weeks, followed by the drug for another 24 weeks. Researchers will measure changes in protein levels in the urine to see if the drug helps protect kidney function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigator Site # 1
RECRUITINGLawrenceville, Georgia, 30046, United States
-
Investigator Site #2
RECRUITINGChula Vista, California, 91910, United States
-
Investigator Site #3
RECRUITINGChicago, Illinois, 60643, United States
-
Investigator Site #4
RECRUITINGChattanooga, Tennessee, 37404, United States
-
Investigator Site #5
RECRUITINGArlington, Texas, 76015, United States
-
Investigator Site #6
RECRUITINGCoral Springs, Florida, 33071, United States
-
Investigator Site #7
RECRUITINGMiami, Florida, 33172, United States
-
Investigator Site #8
RECRUITINGOrlando, Florida, 32806, United States
Conditions
Explore the condition pages connected to this study.